Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GIA 632

Next Previous
Drug Profile

GIA 632

Alternative Names: GIA-632

Latest Information Update: 03 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 24 Feb 2026 Novartis plans a phase IIb trial for Vitiligo, in April 2026 (Parenteral) (NCT07431177)
  • 10 Nov 2025 Phase-II clinical trials in Atopic dermatitis in Singapore, Canada, USA (Parenteral) (NCT07220577)
  • 10 Nov 2025 Novartis Pharmaceuticals plans a phase IIa trial for Atopic Dermatitis in USA, Canada and Singapore (Novartis Pharmaceuticals)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top